← BackProgyny, Inc. · Misc Health & Allied Services, NECPGNY
Low riskNext report: Around Nov 5 (est.)
The short versionA profitable company with steady sales.
Going well
- Profitable
- Sales up 10% last year
- Brings in more cash than it spends
Money moves
- Insiders sold $53K in the last 30 days, all through pre-planned sales
- Institutions cut 1.2% from their holdings in the quarter ending June 2026 (149 bought, 160 sold)
- Held by Ray Dalio (Bridgewater)
Facts from SEC filings, not a recommendation.
What the price means
Price as of Oct 26
$28.14-2.9% that day
- Company value
- $2.2B
- Share price times all shares
- Price vs profit (P/E)
- 30.6x
- You pay about $31 for each $1 of yearly profit
- Price vs sales
- 1.6x
- Company value is 1.6 times a year of sales
- Cash vs value
- 7%
- Cash as a share of company value
From PGNY's last IEX trade and its SEC filings (profits and sales over the last four quarters). A starting point for research, not a verdict.
The business over time
Last 12 quarters, from SEC filings
Sales, Jun '26$350.5M+5.3% vs a year earlier
Sep '23Tap a barJun '26
Last 12 months: $1.3B, up 5.5% from the 12 months before. Over 5 years, sales grew about 30% a year.
Business quality
The checklist Warren Buffett-style investors use. Annual numbers for 2025.- MissReturn on equity 15%+Earns a lot on the money owners have in the business.12.5%
- PassDebt under half of equityNot relying on borrowed money.No debt reported
- MissNet margin 10%+Keeps at least 10 cents of profit from each dollar of sales.4.5%
- MissProfitable every yearSteady profits, not one good year.7 of 9 years
- PassFree cash flow positiveBrings in more cash than it spends to run and grow.$191.8M
- PassShare count not growingNot diluting owners. Falling means buybacks.-10.1% in 3 years
- MissGross margin 40%+Pricing power: sells for well above what it costs to make.23.6%
- Revenue
- $1.3B
- +10.4% vs prior year
- 5-year growth
- +30.2%/yr
- revenue, per year
- Total debt
- None
- 0.00x equity
- Current ratio
- 2.73x
- short-term assets / bills due
From annual reports filed with the SEC. A checklist is a starting point for research, not a verdict.
Latest quarter
Quarter ended Jun 30, 2026- Revenue
- $350.5M
- +5.3% YoY
- EPS
- $0.34
- vs $0.19
- Op. margin
- 11.4%
- +4.1 pts
- Gross margin
- 25.5%
- +1.8 pts
- Free cash flow
- $44.2M
- Share count
- -8.4%
- vs a year ago
Insider rating
Last 90 days
47Mixed
- Pre-planned sales of $154K (weaker signal)
50 is neutral. Buying by more insiders, top executives and bigger stakes raises it. Selling lowers it; pre-planned sales count less.
Weekly insider trend13 weeks agoBoughtSoldThis week
Filing buzz
Last 7 days vs normal
0/ 100
- This week
- 1
- Normal week
- 1.2
- vs normal
- 0.8x
SEC filings of any kind. 50 means a normal week.
Institutional ownership
■Steady-1.2%Institutions cut 1.2% from their holdings. 149 bought, 160 sold. 3 quarters of net selling in a row.
Shares held by institutions79.2M
Sep '24Jun '26
Share count growthYearly rate, last 3 years
-7.0%Cash runwayAt last year's cash burn
Cash flow positiveDebt to equityLatest balance sheet: debt compared with what owners have
No debt reportedShares outstandingLatest reported
77MNext reportAround Nov 5 (est.)Estimated from the same quarter last year
- Results filedAug 6
- Results filedMay 7
- Results filedFeb 26
- Results filedJan 12
- Results filedNov 6, 2025
Insider trades
Open-market buys and sells, last 90 days Bought$00 insiders
Sold$154K2 insiders, 2 pre-planned
| Insider | Trade | Shares | Avg price | Value | Owns after | Date |
|---|
Melissa B CummingsChief Operating Officer | Sell | 2K | $28.00 | $53K | 66K | |
- -2.7% of their holdings
- Pre-planned sale (10b5-1)
- Filed 2 days after
|
Allison SwartzEVP, GC | Sell | 4K | $26.10 | $102K | 76K | |
- -4.9% of their holdings
- Pre-planned sale (10b5-1)
- Filed 5 days after
|
"Owns after" is the insider's holding right after the trade. Pre-planned (10b5-1) sales are set up months ahead, a weaker signal.
Latest filings
Straight from SEC EDGAR
5%+ holder update (passive)Oct 27 · Form SCHEDULE 13G/A ↗SoldMelissa B CummingsChief Operating Officer
1,879 shares at $28.00 · $53K
- -3% of holdings
- Now owns 66,496 shares
- Pre-planned sale (10b5-1)
- Filed 2 days after trade
- Also: Shares withheld for taxes
Planned insider saleOct 14 · Form 144 ↗SoldAllison SwartzEVP, GC
3,903 shares at $26.10 · $102K
- -5% of holdings
- Now owns 75,816 shares
- Pre-planned sale (10b5-1)
- Filed 5 days after trade
Planned insider saleSep 23 · Form 144 ↗Shares withheld for taxesGeoffrey ClappChief Product Officer
819 shares at $27.38 · $22K
- -1% of holdings
- Now owns 59,009 shares
- Filed 4 days after trade
SoldKevin K GordonDirector
11,500 shares at $27.12 · $312K
- -63% of holdings
- Now owns 6,792 shares
- Not a pre-planned sale
- Filed 8 days after trade
- Also: Option exercise, Shares withheld for taxes
SoldKevin K GordonDirector
11,500 shares at $27.94 · $321K
- -63% of holdings
- Now owns 6,792 shares
- Not a pre-planned sale
- Filed 4 days after trade
- Also: Option exercise, Shares withheld for taxes
Planned insider saleSep 10 · Form 144 ↗Shares withheld for taxesMark S. LivingstonCHIEF FINANCIAL OFFICER
479 shares at $26.61 · $13K
- -1% of holdings
- Now owns 72,453 shares
- Filed 4 days after trade
Insider tradeSep 8 · Form 4 ↗Insider tradeSep 8 · Form 4 ↗Insider tradeSep 4 · Form 4 ↗Insider tradeSep 1 · Form 4 ↗Quarterly reportAug 7 · Form 10-Q ↗